Island Pharmaceuticals Locks in GMP Manufacturing to Push Marburg Drug Toward FDA

Island Pharmaceuticals advances Galidesivir GMP manufacturing with global CRDMO

Island Pharmaceuticals (ASX: ILA) has executed a GMP manufacturing agreement with PI Health Sciences (PIHS) for Galidesivir, marking a material step in the transition of the antiviral asset from development-stage toward a commercially viable biodefence countermeasure. Manufacturing activities have commenced, with GMP-grade product expected to be received in the coming months. The campaign is designed to validate and scale production to a level appropriate for late-stage development, supporting the company’s planned pivotal Marburg study under the US FDA’s Animal Rule pathway while extending strategic flexibility for broader biodefence and outbreak response opportunities, including the current Bundibugyo Ebola outbreak.

What this GMP campaign covers and why it matters

Scope of the PIHS manufacturing agreement

The agreement with PIHS encompasses four core components:

• Analytical method validation
• Reference standard preparation
• Stability studies
• Manufacture of Galidesivir to pivotal study specifications

PIHS is a global contract research, development and manufacturing organisation (CRDMO) specialising in the development and manufacture of active pharmaceutical ingredients for regulated markets. The company operates GMP compliant manufacturing facilities across Europe and Asia, providing analytical development, process optimisation and GMP manufacturing services to biotechnology and pharmaceutical companies globally.

What GMP manufacturing means for biodefence drug development

Good Manufacturing Practice (GMP) refers to the quality and manufacturing standards required by regulators to ensure a drug product is consistently produced to a defined level of quality, safety and purity. In plain terms, it is the standard a manufacturer must meet before a product can be used in pivotal clinical studies, submitted to a regulator, or procured by a government agency.

For a biodefence program like Galidesivir, GMP-grade supply is a non-negotiable prerequisite at this stage. Without it, the company cannot conduct a pivotal efficacy study, advance a regulatory submission to the FDA, or engage with government procurement pathways.

Critically, Island’s existing Galidesivir inventory remains available to support planned dose optimisation studies. The new GMP-grade batch being manufactured by PIHS is specifically earmarked for the pivotal efficacy study that is expected to form the cornerstone of a future FDA submission under the Animal Rule pathway.

Building toward FDA submission and government procurement

The Animal Rule pathway to potential FDA approval

The FDA’s Animal Rule pathway allows drug approval based on animal efficacy data in circumstances where human efficacy trials are not ethical or feasible, combined with human safety data. This is the appropriate regulatory mechanism for a disease such as Marburg Virus Disease, where conducting controlled human efficacy trials is not practicable. According to the announcement, pivotal study initiatives are expected to represent the final requirements prior to a potential FDA submission, making the new GMP-grade supply a direct enabler of that regulatory endpoint.

Broader biodefence optionality unlocked

Access to GMP-grade product extends Island’s strategic positioning well beyond the Marburg program. The company has identified a range of near-term opportunities the supply base could support:

1. Marburg Virus Disease — primary focus; pivotal study underpinned by new GMP-grade supply from PIHS
2. Ebola (including current Bundibugyo outbreak) — Galidesivir has previously demonstrated broad-spectrum antiviral activity against Ebola
3. Other high-consequence RNA viruses (MERS, Zika, Yellow Fever) — part of Galidesivir’s documented activity profile across more than 20 RNA viruses
4. Government procurement pathways — GMP supply establishes the manufacturing, analytical and quality systems required for future regulatory and procurement activities

In a global environment of heightened biodefence preparedness and recurring infectious disease outbreaks, access to clinical-grade drug supply is an increasingly material strategic asset. The commencement of this campaign positions Galidesivir as an actively advancing biodefence program rather than a legacy development asset.

CEO commentary

Dr David Foster, CEO and Managing Director

“With manufacturing now underway, access to non-human primates close to finalised, and our regulatory pathway continuing to take shape, we are systematically building the critical elements required to position Galidesivir as a potential countermeasure for Marburg Virus Disease and other high-consequence viral threats.”

What’s next for Island Pharmaceuticals (ASX: ILA)

Near-term catalysts for the Galidesivir program include:

• Receipt of GMP-grade Galidesivir from PIHS expected in coming months
• Trial partner agreements for dose optimisation studies described as imminent
• Non-human primate access close to finalised
• Regulatory pathway for the Marburg program continuing to take shape
• Potential engagement with biodefence and outbreak response opportunities as they arise, including the current Ebola outbreak

Island is systematically assembling the manufacturing, quality and regulatory framework required to support potential approval and government procurement. The progression positions Galidesivir as an actively advancing biodefence countermeasure with a clear pathway toward FDA submission under the Animal Rule.

Don’t Miss the Next Biodefence Breakthrough on the ASX

Big News Blast delivers FREE breaking ASX healthcare and biotech news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000+ subscribers are already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.